dc.contributor.author | Tan, Ken-Soon | |
dc.contributor.author | Vardesk, Deepak L. | |
dc.contributor.author | Raman, Padma | |
dc.contributor.author | Frazier, Jeremy | |
dc.contributor.author | Jarvis, Elizabeth | |
dc.date.accessioned | 2015-02-17 | |
dc.date.accessioned | 2017-03-01T23:45:30Z | |
dc.date.available | 2015-06-09T05:10:20Z | |
dc.date.available | 2017-03-01T23:45:30Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 2161-0959 | |
dc.identifier.doi | 10.4172/2161-0959.1000157 | |
dc.identifier.uri | http://hdl.handle.net/10072/67927 | |
dc.description.abstract | Aim: Is once daily low dose extended release niacin effective at lowering phosphate?
Background: Serum phosphate levels correlate with mortality in dialysis patients. Current phosphate binders often cause side-effects leading to poor compliance. Niacin has previously been shown to lower serum phosphate in patients with kidney disease. However, at doses previously used (≥ 1 g daily), it is poorly tolerated. Slo-niacin® is a extended release formulation taken once daily.
Methods: The study was a single-centre double-blind placebo-controlled randomised cross-over trial in haemodialysis patients. All patients received both active treatment (500 mg Slo-niacin® daily) and matching placebo for 8 weeks each with intervening 2 week washout phase. All patients continued usual phosphate binders and Cinacalcet/vitamin D analogues, although no dose adjustments were permitted. Patients were recruited if they were >18yo, not pregnant and serum phosphate 4 weeks prior to commencement was ≥ 1.8 mmol/L. All gave informed consent.
Results: 33 patients were recruited. 1 patient died following emergency cardiac surgery during placebo phase & 3 patients withdrew (2 niacin, 1 placebo, p=NS) leaving 29 for analysis. Extended release niacin significantly reduced serum phosphate compared to placebo (p<0.0014, t-test and ANOVA). Mean absolute difference between groups was -0.35 mmol/L (95% CI -0.62 mmol/L to -0.08 mmol/L) in favour of niacin (p ~ 0.01, t-test). Neither treatment altered calcium levels. Extended release niacin was well tolerated apart from early mild flushing which improved with time.
Conclusion: Once daily low dose extended-release niacin is effective at lowering serum phosphate. | |
dc.description.peerreviewed | No | |
dc.description.publicationstatus | Yes | |
dc.format.extent | 336998 bytes | |
dc.format.mimetype | application/pdf | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | OMICS Group International | |
dc.publisher.place | United States | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 1000157-1 | |
dc.relation.ispartofpageto | 1000157-6 | |
dc.relation.ispartofissue | 3 | |
dc.relation.ispartofjournal | Journal of Nephrology & Therapeutics | |
dc.relation.ispartofvolume | 4 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Medical and Health Sciences not elsewhere classified | |
dc.subject.fieldofresearchcode | 119999 | |
dc.title | The Slo-Niacin Trial: A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Extended Release Niacin for Phosphate Lowering in Haemodialysis Patients | |
dc.type | Journal article | |
dc.type.description | C2 - Articles (Other) | |
dc.type.code | c2 | |
gro.faculty | Griffith Health Faculty | |
gro.rights.copyright | © 2014 Tan KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
gro.date.issued | 2015-06-09T05:10:20Z | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Tan, Ken-Soon | |